

Special Issue

Recent Advances in Drug Therapy for Glioblastoma

Message from the Guest Editor

Glioblastomas are highly aggressive tumors of the brain that are resistant to radiotherapy and temozolomide, the only treatments currently available. Therefore, effort is necessary to find novel therapeutic approaches and alternative targets in order to enhance the survival of these patients. In fact, the median overall survival after surgery and the standard treatment with radiotherapy and temozolomide is 14–16 months, and there is no standard second line treatment since lomustine and bevacizumab have modest efficacy. Despite the lack of clear advances in the treatment of glioblastoma, molecular and cellular studies have significantly improved the knowledge of glioma biology, particularly in the fields of microenvironment regulation, tumor immunology, and in oncogenic signaling pathways control. Clinical and translational researchers are getting the most out of these new findings in order to develop new drugs targeting not only tumor growth pathways but also the glioma microenvironment. In this respect, this Special Issue will focus on new therapeutic approaches that try to overcome previous failures in glioblastoma management.

Guest Editor

Dr. Juan Manuel Sepúlveda-Sánchez

Instituto de investigación I+12, Hospital 12 de Octubre, 28041 Madrid, Spain

Deadline for manuscript submissions

closed (30 April 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/95211

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)